Abstract 2300
Background
AXL expression promotes tumour growth, angiogenesis, epithelial to mesenchymal transition (EMT), resistance to CT and targeted agents. AXL is overexpressed in CRC. We aimed to evaluate AXL expression in mCRC pts and to correlate it with clinical outcomes.
Methods
AXL expression was assessed by immunohistochemistry in tumor samples of a consecutive series of 109 mCRC pts (75 RAS mutant and 34 RAS WT) treated at our Institution and 68 mCRC RAS WT pts enrolled in CAPRI-GOIM trial. Pts received a first line treatment according to RAS status: RAS mutant pts (n = 75) received CT + anti-angiogenic drugs, RAS WT pts (n = 102) CT + cetuximab.
Results
AXL stained positively in 20/177 samples with different intensity: 13 weak, 5 moderate, 2 intense. In RAS WT cohort 9/102 cases (9%) were positive while in RAS mutant 11/75 (15%). Tumor stroma was assessable in 166 samples. AXL expression was high (moderate + intense) in 47/96 (49%) RAS WT and in 28/70 (40%) RAS mutant cases. No significant correlation was found between AXL expression and clinico-patological features. In RAS WT cohort, AXL positive pts had a significantly worse median PFS [4.3 m (CI95% 3.2-5.5) vs 12.1 m (CI95% 11.0-13.3) p = 0.001], in RAS mutant no impact on PFS was observed. AXL expression in tumor was a negative prognostic factor in both cohorts although statistical significance was reached only in RAS mutant [median OS: 30.2 m (CI95% 18.4-42.0) vs 20.1 m (CI95% 10.6-29.6) p = 0.007]. Intriguingly, high AXL expression in stroma correlated with lower median OS in both cohorts (Table).Table: 96P
| Cohort | Median OS (months - CI95%) AXL expression in tumor | Median PFS (months - CI95%) AXL expression in tumor | Median OS (months - CI95%) AXL expression in stroma | Median PFS (months - CI95%) AXL expression in stroma | ||||
|---|---|---|---|---|---|---|---|---|
| N (tumor) / N (stroma) | AXL positive | AXL negative | AXL positive | AXL negative | AXL high | AXL low | AXL high | AXL low |
| Overall population N = 177 / N = 166 | 20.1 (12.8-27.4) | 36.5 (30.6-42.3 ) p = 0.02 | - | - | 25.3 (21.4-29.3) | 46.4 (34.6-58.2) p = 0.003 | - | - |
| RAS WT (CT + cetuximab) N = 102 / N = 96 | 23.0 (0.0- 63.3) | 39.8 (30.2– 49.4) p = 0.66 | 4.3 (3.2- 5.5) | 12.1 (11.0– 13.3) p = 0.001 | 28.8 (17.4- 40.1) | 47.7 (29.7– 65.7) p = 0.021 | 10.7 (8.4- 13.0) | 12.4 (9.6– 15.2) p = 0.06 |
| RAS mutant (CT + anti-angiogenic) N = 75 / N = 70 | 20.1 (10.6- 29.6) | 30.2 (18.4- 42.0) p = 0.007 | 8.9 (5.4- 12.4) | 9.1 (7.6- 10.7) p = 0.444 | 24.2 (18.2- 30.1) | 37.7 (16.8- 58.6) p = 0.026 | 8.9 (6.1- 11.8) | 8.6 (7.3- 10.0) p = 0.53 |
Conclusions
AXL, marker of EMT phenotype, might represent an additional predictive biomarker of lack of efficacy in RAS WT mCRC pts treated with CT + cetuximab. Moreover, its expression in tumor and stroma might have a negative prognostic relevance in mCRC. Targeting AXL could overcome resistance to anti-epidermal growth factor receptor and represent a novel therapeutic strategy in mCRC.
Clinical trial identification
CAPRI-GOIM Trial = EudraCT 2009-014041-81.
Legal entity responsible for the study
Department of Precision Medicine, Università degli Studi della Campania "Luigi Vanvitelli".
Funding
Grant by AIRC = MFAG-2015-ID: 7778.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.